Today was a pretty big, even enormous, letdown. I was really...

Today was a pretty big, even enormous, letdown. I was really very sure that even if the market was fickle, the science wasn't. I was wrong.

These results are so bad it looks as though the trial participants would have been no worse off if they had just tossed the pill and simply drank the water neat.

I'd like to know whether the company has any data to prove that the treated group was in fact treated. This data looks for all the world like everyone in the study got the placebo.

Right now, what's needed most is a letter from management to shareholders outlining a realistic plan forward.

First and foremost, I need to know that Metabolic have secure rights to ACV1, and that they are doing everything they can to expedite and ensure the rapid movement of this drug through trials and to market. In circumstances like this, I have seen contractual relationships break down. I wouldn't be surprised if poachers were camped out on Bruce Livett's doorstep at this moment.

Second, I wnat to know what steps are being taken to confirm the efficacy of AOF9604 as an osteoporosis treatment in humans. I'd like to know why a subset of the volunteers in the weight trial (post menopausal women in all dosage groups) weren't given bone density scans in an dout of the study. Maybe it's not scientific, but the results could have provided a sense of whether the drug could be advanced. In any case human trials need to be brought forward right now.

I have owned stock in this company for four years. This is the second boom-bust cycle I have ridden out; this one ithe more serious for the company because of the blunt finality of the present termination of the obesity indication of AOD9604.

Management has the crucial and immeidate task of convincing folks like me that there is something going on with the company that's worth sticking around for.